Agilent

Trusted Answers

PD-L1 IHC 22C3 pharmDx in TNBC

Your Report. A Patient's Future.

In triple-negative breast cancer (TNBC), PD-L1 IHC 22C3 pharmDx (SK006) is the only PD-L1 companion diagnostic assay approved by the FDA to identify patients for treatment with KEYTRUDA® (pembrolizumab).

For training in TNBC Combined Positive Score (CPS) contact: pathology.solutions@agilent.com